With its purchase of Washington-based Seagen, Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
GREECE - 2022/03/29: In this photo illustration, a stack of pills is displayed on a screen with the Pfizer logo in the background.
"We are not buying the golden eggs," he said. "We are acquiring the goose that is laying the golden eggs."based Seagen Inc. specializes in working with antibody-drug conjugate, or ADC, technology. Its key products use lab-made proteins called monoclonal antibodies that seek out cancer cells to help deliver a cancer-killing drug while sparing surrounding tissue.
"We think this really changes dramatically the oncology presence of Pfizer, makes it one of a kind," Bourla said. The company, which changed its name from Seattle Genetics in 2020, saw total revenue grow about 25% last year to nearly $2 billion. Seagen also shaved its loss to $610 million from $674 million in 2021.Pfizer booked about $100 billion in total revenue last year and has been flush with cash thanks to sales of its COVID-19 vaccine and treatment, Comirnaty and Paxlovid.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Pfizer buys Washington-based Seagen for $43 billion, boosts access to cancer drugsWith its purchase of Washington-based Seagen, Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue. FOX13
Consulte Mais informação »
Pfizer Agrees to Buy Seagen for $43 BillionThe New York drugmaker would pay $229 a share in cash for the biotech company and its pioneering cancer treatments.
Consulte Mais informação »
Pfizer looks beyond COVID sales with $43 bln deal for cancer drugmaker SeagenPfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
Consulte Mais informação »
Pfizer to buy cancer drugmaker Seagen for $43 billionNEW: Pfizer said it has agreed to buy cancer drugmaker Seagen for $43 billion in cash. It's the largest pharma deal since Abbvie bought Allergan in 2020.
Consulte Mais informação »
Pfizer buys Seagen for $43B, boosts access to cancer drugsPfizer will spend $43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay $229 per Seagen share.
Consulte Mais informação »
Pfizer looks past COVID with $43 bln deal for cancer drug innovator SeagenPfizer Inc struck a $43 billion deal for Seagen Inc to add innovative targeted therapies to its portfolio of cancer treatments as it braces for a steep fall in COVID-19 product sales and stiff competition for some top sellers.
Consulte Mais informação »